COPD drug roflumilast tested as depression booster
NCT ID NCT06860958
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether adding roflumilast (a COPD drug) to the antidepressant fluoxetine helps people with major depression who haven't responded well to treatment. Sixty adults with moderate-to-severe depression will take either the combination or a placebo for 8 weeks. The main goal is to see if depression scores improve more with the added drug.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Roflumilast (a drug for COPD) combined with fluoxetine (an antidepressant)
What this could lead to
If it works, this could offer a new option for people with depression who don't get better with standard antidepressants alone.
What could go wrong
This is a small, early-phase trial with only 60 people. Roflumilast can cause nausea and vomiting, and it's not yet proven to help depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSIVE DISORDER, MAJOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tanta Unuversity
RECRUITINGTanta, 31527, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••